The Latest Cardiac and Vascular News
PARIS, May 22, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced five-year results from the FAME 2 study, which showed that patients had fewer major adverse cardiac events (MACE) when they received a heart stent guided by Abbott’s fractional flow reserve (FFR) diagnostic tool in combination with medical therapy compared to patients […]
ABBOTT PARK, Ill., May 3, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance of the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™. Advisor HD Grid employs a new design that allows physicians to see things differently, capturing and analyzing data in a novel manner to create […]
ABBOTT PARK, Ill., May 2, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced that Japan’s Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions of XIENCE with an enhanced stent design, a new delivery […]
ABBOTT PARK, Ill., April 18, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2018. First-quarter worldwide sales of $7.4 billion increased 16.7 percent on a reported basis and 6.9 percent on an organic* basis. Reported diluted EPS from continuing operations under GAAP was $0.23 in the first quarter. Adjusted diluted EPS from […]
ABBOTT PARK, Ill., April 11, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced the initiation of a clinical trial evaluating long-term outcomes of patients who undergo stent implantation guided by high-resolution light-based imaging technology—called optical coherence tomography (OCT)—compared to a common X-ray-guided technique called angiography. The trial (ILUMIEN IV) is the first large-scale randomized global […]
ABBOTT PARK, Ill., March 29, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS™ HF System. The GUIDE-HF trial will study whether the CardioMEMS device can improve survival and quality of life for people living with New York Heart Association (NYHA) Class II – IV heart failure. The […]
ABBOTT PARK, Ill., March 21, 2018 /PRNewswire/ — Abbott (NYSE: ABT) will announce its first-quarter 2018 financial results on Wednesday, April 18, 2018, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m.Eastern), and will be accessible through Abbott’s Investor Relations website […]
ABBOTT PARK, Ill., March 19, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan granted national reimbursement for the company’s MitraClip therapy to treat people with mitral regurgitation, a serious, progressive heart disease in which the mitral valve does not close properly, […]
ORLANDO, Fla., March 11, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced new late-breaking clinical trial data from the MOMENTUM 3 clinical study, the largest left ventricular assist device (LVAD) trial in the world to evaluate patients in need of both short-term and long-term support in a single study. The data were published online […]
ABBOTT PARK, Ill., March 6, 2018 /PRNewswire/ — Abbott today announced the U.S. Food and Drug Administration (FDA) approved the Masters HP™ 15mm rotatable mechanical heart valve, the world’s smallest mechanical heart valve, that will allow doctors to treat babies and toddlers in need of a mitral or aortic valve replacement. Until […]
